Newly Published Health Economics Study Demonstrates In-Office Ear Tube Procedures with Hummingbird TTS Significantly Reduce Healthcare Costs

GOLDEN VALLEY, Minn.--(BUSINESS WIRE)-- Preceptis Medical, Inc., a pioneer in pediatric ENT innovation, today announced the publication of a health economic study assessing the financial impact of shifting pediatric tympanostomy tube (ear tube) placement from operating room to in-office settings. The analysis, published in the Journal of Medical Economics, demonstrates significant cost savings potential for Commercial and Medicaid health insurance payers that provide access to in-office ear tube procedures utilizing the Hummingbird ® Tympanostomy Tube System (TTS).
"This analysis demonstrates that payers can also realize meaningful cost savings, even when accounting for the additional resources required to treat children in-office." Dr. Gene Liu, Study Co-Author
Key findings from the study include 1:
Current costs of ear tube surgeries are estimated to be $3.5 billion annually for the US Healthcare System:
Ear tube surgeries in a Hospital Outpatient Department (HOPD) on average cost over $5,700 for a commercial plan and $2,100 for a Medicaid plan
Higher costs of OR-based surgeries are driven by the costs of the operating room, anesthesia, pre- and post-surgery care, and additional pre-operative testing
Shifting ear tube procedures from the OR to the Office could save:
Up to $3,743 per patient (65% cost savings) for a Commercial health plan
Up to $519 per patient (24% cost savings) for a Medicaid health plan
The procedural cost savings were significant even after accounting for the increased costs of pediatric in-office ear tube procedures, including the costs of the Hummingbird ® TTS
Pediatric ear tube surgeries historically have been performed in the operating room (OR) under general anesthesia. However, the procedure can be safely and effectively performed in an office setting by using the Hummingbird ® TTS, helping pediatric patients avoid risks associated with operating room surgeries and general anesthesia exposure 2. This analysis demonstrates that in addition to the important clinical and safety benefits, Payers may also experience significant cost savings.
'Shifting ear tube placement into the office with the Hummingbird ® Device has improved patient access and offered families an important alternative to OR-based surgeries,' said Dr. Gene Liu, Pediatric Otolaryngologist at Cedars-Sinai Medical Center. 'This analysis demonstrates that payers can also realize meaningful cost savings, even when accounting for the additional resources required to treat children in-office. My hope is that these findings encourage payers to establish sustainable reimbursement rates that expand access to this safe and cost-effective option.'
To support patient access to pediatric in-office ear tube procedures with tympanostomy tube delivery devices, the Centers for Medicare & Medicaid Services (CMS) established add-on HCPCS Code (+G0561) in the 2025 Physician Fee Schedule 3. CMS stated in the 2025 PFS, 'These minimally invasive, in-office procedures can offer significant benefits, including reduced risks associated with general anesthesia, quicker recovery, fewer infections, and improved access to care.' The new add-on G code facilitates fair reimbursement to providers for the incremental work and practice expenses (including device costs) involved in performing pediatric ear tube procedures in-office. This is the first economic study to evaluate the economic impact of utilizing the add-on code +G0561.
'This study reinforces what we have seen in our Health System, where we have been offering in-office ear tube procedures with the Hummingbird Device since 2021,' shared Dr. Mark Gerber, Pediatric Otolaryngologist at Phoenix Children's Hospital. 'Providing a mechanism for reimbursement for the incremental costs of the pediatric procedure will remove a significant barrier to utilization and save healthcare dollars.'
About Preceptis Medical
Founded in 2011, Preceptis Medical is an innovative medical technology company dedicated to providing less invasive ear tube procedure options for pediatric patients. The FDA-cleared Hummingbird ® Tympanostomy Tube System (TTS) streamlines ear tube placement, which enables the procedure to be performed with only a topical anesthetic. The Hummingbird, indicated for use in patients 6 months of age and older, provides a simple and efficient option for ENTs and parents while reducing healthcare costs. For more information, please visit https://www.hummingbirdeartubes.com/
Moynihan, M., Ross, R., Delgado, J., Gerber, M., & Liu, G. (2025). Economic impact of in-office pediatric tympanostomy tube placement using a tympanostomy tube delivery device in a commercially- and Medicaid-insured US population. Journal of Medical Economics, 28 (1), 899–909
Truitt MD, Theodore O., et al. 'In-office insertion tympanostomy tubes in children using single-pass device' Laryngoscope Investigative Otolaryngology. 2021;6:325-331.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

an hour ago

• Business Wire

Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation

SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. ('Candid'), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced key operational and clinical milestones for its two lead clinical stage programs, cizutamig (BCMA TCE) and CND261 (CD20 TCE). Candid launched in the second half of 2024 with $370 million in financing and two in-licensed TCEs that had completed full Phase 1 dose escalation studies in oncology patients. Emerging clinical data with TCEs have solidified our confidence that TCEs can become the most compelling modality across a range of diseases. Share 'We founded Candid on the conviction that T-cell engagers would become the largest therapeutic class in autoimmune diseases, surpassing the commercial success of TNF inhibitors such as Humira,' said Dr. Ken Song, Chairman, President, and Chief Executive Officer of Candid. 'We are hyperfocused on execution to generate clinical data. Over the past few quarters, we have prioritized disease indications and built a foundation of key CMC and clinical operational activities to set a new benchmark for innovation, scale, and speed. Emerging clinical data with TCEs have solidified our confidence that TCEs can become the most compelling modality across a range of diseases.' Key Highlights Reinforcing Candid's Leadership Position: First patients dosed with cizutamig and CND261: Patients with refractory rheumatoid arthritis and systemic sclerosis have been dosed at therapeutically active doses. Both TCEs have been well tolerated and patients have shown early signs of promising clinical response and disease improvement. Industry-leading clinical study pipeline in motion: Clinical studies are now in progress for IgA Nephropathy, Myasthenia Gravis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Systemic Sclerosis. Additional clinical studies in high-value disease indications slated to launch in the 2H 2025. Studies are designed to evaluate safety, pharmacokinetics, pharmacodynamic effects, and early signs of efficacy in patients with immunology and inflammatory diseases. CMC activities completed to enable global clinical trials: Candid has invested significant resources to build an integrated Chemistry, Manufacturing, and Controls (CMC) infrastructure to support global development with the completion of several new drug product manufacturing runs. Subcutaneous dosing formulations for both cizutamig and CND261 have been established. Strategic establishment of China operations: To support clinical execution across multiple geographies, Candid has established a fully staffed legal entity in China. The China based team includes professionals with deep expertise in regulatory, clinical development, and clinical operations. With unmatched executional momentum and differentiated programs, Candid Therapeutics is defining a new future in immunology through its commitment to TCEs in autoimmune diseases. Additional trial initiations and clinical data disclosures are anticipated in the coming quarters. About Candid Therapeutics Candid Therapeutics is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune and inflammatory diseases through novel T-cell engager (TCE) platforms. Candid is advancing two lead B-cell depleting TCE antibody drug candidates, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors. About Cizutamig Cizutamig is a bispecific antibody designed to simultaneously bind B-cell maturation antigen (BCMA) on B-cells and CD3 on T-cells, enabling T-cell–mediated cytotoxicity against BCMA-expressing B-cells. Originally developed and clinically evaluated in multiple myeloma, cizutamig has demonstrated patient experience in oncology settings and is now being investigated in autoimmune diseases where pathogenic B-cells play a critical role in disease progression. Cizutamig has the potential to deliver deep and selective B-cell depletion through its dual-targeting mechanism, offering a novel approach for treating a broad spectrum of immune-mediated disorders. About CND261 CND261 is a bispecific antibody designed to target CD20 on B-cells and CD3 on T-cells, enabling T-cell mediated cytotoxicity against CD20-expressing B-cells. Engineered with low CD3 affinity, CND261 is optimized to reduce the risk of excessive T-cell activation while maintaining potent and selective B-cell depletion. The molecule has demonstrated patient experience in B-cell malignancies and is now being investigated in autoimmune diseases where pathogenic B-cells contribute to disease progression. CND261 represents a promising therapeutic candidate for immune-mediated disorders with the potential for improved safety and efficacy through its targeted mechanism of action.

The Hill

2 hours ago

• The Hill

Trump's megabill hits more trouble as Senate conservatives demand changes

The Senate version of legislation to enact President Trump's agenda is hitting new turbulence as conservatives led by Sens. Ron Johnson (R-Wis.), Rick Scott (R-Fla.) and Mike Lee (R-Utah) are demanding deeper spending cuts to address the nation's $2.2 trillion annual deficit. Senate Majority Leader John Thune (R-S.D.) has focused this week on addressing the concerns of Senate GOP colleagues such as Sens. Josh Hawley (Mo.) and Lisa Murkowski (Alaska), who raised alarms about cuts to federal Medicaid spending. But Thune has to worry about his right flank as Johnson and his allies are threatening to hold up the bill unless GOP leaders agree to deeper cuts to federal Medicaid spending and a faster rollback of the renewable energy tax credits enacted under former President Biden. Johnson, Lee and Scott are threatening to vote as a bloc against the bill next week unless it undergoes significant changes. Thune plans to bring the bill to the floor Wednesday or Thursday next week, but he may not have enough votes to proceed on the legislation, say Republican senators. 'There's no way I vote for this thing next week,' Johnson told reporters. 'I don't want to go the Nancy Pelosi route, 'You got to pass this bill to know what's in it,'' he added, referring to the Democratic Speaker emerita who represents California. Johnson noted that senators are taking a closer look at a proposal offered by Scott to significantly reduce the Federal Medical Assistance Percentage (FMAP), or the federal government's share of Medicaid spending, in states that expanded the program under former President Obama's Affordable Care Act (ACA). Lee is pushing for a fuller phaseout of the renewable energy subsidies enacted by Democrats in the Inflation Reduction Act (IRA). 'Mike is handling the IRA provisions of this, Rick Scott is handling the Medicaid. You need to satisfy those two, too. All three of us have to be yes or none of us are yes,' Johnson said. Scott, who founded the Columbia Hospital Corp. and went on to run Columbia/HCA Healthcare Corp., one of the world's largest health care companies, wants to dramatically cut the 90 percent federal match for states that expanded Medicaid under the ACA. 'The focus should be on how do we take care of what Medicaid's original purpose was? It's children and the chronically ill,' he said. Scott argues that able-bodied low-income adults are drawing far too much of Medicaid spending in states that expanded the program, such as California and New York. 'Half the people, half the adults that are on Medicaid under the expanded FMAP are not working,' he said, adding that these people are not disabled. 'We're running $2 trillion deficits.' Scott says Medicaid shouldn't pay out more than Medicare and that states should not be eligible for expanded federal Medicaid payments for new enrollees after two years. He also wants to further crack down on states' use of health care provider taxes to increase their share of federal Medicaid spending. That sets up a fight next week with Senate Republican colleagues who have balked at the cuts to Medicaid spending unveiled Monday by Senate Finance Committee Chair Mike Crapo (R-Idaho). The current Senate bill would reduce the maximum permitted provider tax rate from 6 percent to 3.5 percent by 2031. The Florida senator said colleagues such as Hawley and Sen. Susan Collins (R-Maine), who are worried about limiting health care provider taxes, have a 'legitimate concern' about the fate of rural hospitals. But he argued that the high rate of Medicaid spending won't solve their problems. Collins has proposed a 'provider-relief fund' to the bill to help offset Medicaid cuts for rural hospitals, nursing homes and community health centers. Lee, the Utah Republican, meanwhile is calling for a more rapid and complete phaseout of renewable energy subsidies in the bill and for tougher language to keep tax benefits from going to immigrants who entered the country illegally. 'Green New Deal subsidies that don't terminate by 2028 will effectively become permanent. If you don't want them to be permanent, tell your senators!' Lee posted on social platform X. Language released Monday by the Senate Finance Committee would extend tax credits for hydropower, nuclear and geothermal energy into the 2030s. A faster and broader phaseout of clean energy subsidies would be opposed by Republican senators such as Murkowski, Jerry Moran (Kan.), John Curtis (Utah) and Thom Tillis (N.C.), who warn that a sudden termination of federal support would disrupt the renewable fuel industry, cost jobs and strand billions of dollars in investment. Yet Senate conservatives are ready for a showdown, arguing the deficit poses a major threat to the U.S. economy. 'The deficit will eat us alive if we don't get it under control. If not us, who? If not now, when?' Lee posted Thursday on X. Johnson said Trump promised to balance the budget but argued 'the bill before us does not do it' and will instead worsen deficits over the next decade. He said while the spending cuts in the legislation are 'the most spending reduction we've had ever,' the 'spending increase is unprecedented, 10 times more.' 'Look at the numbers,' he said. The Congressional Budget Office unveiled a new projection that the House-passed bill to enact Trump's agenda would add $3.4 trillion to the debt.

Yahoo

5 hours ago

• Yahoo

UnitedHealth's Rebound: Hidden Strength or Hiding Weakness?

Recently, UnitedHealth Group (UNH, Financial) has been the subject of many headlines because of DOJ probes, kickback accusations in nursing homes, and a shocking departure of its CEO. In addition, the value of its shares has dropped by almost 50%. Yet, underneath the news, the business is still strong. Health insurance remains important and strong throughout economic downturns and doesn't react to changes in global trade. In the aftermath, a clear development can be noticed as Stephen Hemsley was appointed CEO again and bought a large amount of stock which fueled a quick increase in share prices. Warning! GuruFocus has detected 4 Warning Sign with UNH. This is real conviction. UnitedHealth is focusing more on Medicaid-managed care, widening value-based care with Optum, and looking into growing its business in dual-eligible and long-term care. The company's financials confirm the trend since earnings have quadrupled in ten years, cash flow is strong, and insiders are buying in. In short, UnitedHealth is using the uncertainty to its advantage. Long-term investors may find the current price as an attractive chance to enter a company that has shown lasting and solid growth. UnitedHealth Group is the biggest health insurer in the United States and ranks highly internationally in healthcare. Its two key segments, UnitedHealthcare and Optum, give people health benefits, pharmacy services, data analysis, and healthcare. More than 150 million people are helped by this company, which is continuing to expand by combining operations and offering value-based care. The company provides insurance through commercial, Medicare, and Medicaid markets, and Optum sparks new ideas in care coordination and pharmaceutical services. UnitedHealth is smartly diversified. The company is doing well due to managed care growth, making money from healthcare improvements, and strategically serving top segments thanks to Optum doing the main work. Medicaid managed care expansion capturing state-level shifts: The move of Medicaid recipients from fee-for-service to managed care can bring huge benefits to UnitedHealth. According to industry statistics, UNH and four other large insurers cover over 50% of people in Medicaid-managed care across the nation. So, when several hundred thousand to millions switch plans, it has a huge effect on the company's finances. Since monthly premiums for complex patients in these states are $600$800, New York, Pennsylvania, and Michigan could add hundreds of millions of dollars to their annual premium earnings. Because of its connections with states, UNH is in a good position to win a major share of this revenue. Value-based care & optum scale turning outcomes into profit: Optum, which drives UNH's value-based approach, recorded $253 billion in revenue in 2024, which was 12% higher than the previous year, and $16.7 billion in operating income. Currently, Optum Health works with close to 4.7 million people in value-based contracts and plans to add another 650k in 2025. Focus on patient care and cost savings are the main aims of these models, and UNH supports this. When Optum grows its care coordination and home services, shared-savings revenue plays a bigger role, already bringing in hundreds of millions and capable of much more. High-Value segments target the dual-eligible and long-term care markets: Instead of raising its volume, UNH is focusing on high-paying customer groups, such as those with both Medicare and Medicaid and patients needing long-term care. Dual-eligibles may receive $2,500 monthly, which means each person will get $30,000 annually. Currently, UNH serves about 500k people, but if it could capture just 2 million of the national enrollments, it could earn $45 billion in annual premiums. Vertical integration with optum: Thanks to Optum, UNH has all its services combined, including pharmacy (over 1.62 billion scripts were handled by OptumRx in 2024), care delivery, data analysis, and provider management. Because of this integration, UNH is ahead in long-term care, managing care effectively, reducing expenses, and boosting results, which other organizations don't have. Overall, UnitedHealth is a leader that is making steady earnings now and is prepared to capture the future of healthcare and population wellness. Now, let's investigate the financial side of UnitedHealth Group. The company had good first-quarter earnings, but it sent a cautious message for the coming months. UnitedHealth Group's quarterly revenue of $109.6 billion was $10 billion higher than the same period last year, showing how much both UnitedHealthcare and Optum are growing. While adjusted EPS of $7.20 surpassed $6.91 from the earlier period, the company adjusted its full-year forecast down to expect adjusted EPS of $26.00 to $26.50. So, what leads to this change of tone? While UnitedHealthcare welcomed 780,000 new members, increased use of health services in Medicare Advantage by its customers caused the company's medical costs to increase above expectations. Because more people needed outpatient and physician care, the medical care ratio rose to 84.8%. For healthcare delivery, this is not necessarily an issue, yet it can still hurt business if prices fall short. Meanwhile, Optum Health experienced challenges with a more diverse member group and reduced payments due to less involvement among members in 2024. Even so, Optum achieved a $63.9 billion revenue thanks to its Rx division, which filled 408 million adjusted scripts. UNH is also operating efficiently, with its operating cost ratio now 12.4%, free cash flow at $5.5 billion, and a high 26.8% return on equity. The company also gave $5 billion back to its shareholders. All in all, UNH's basics are solid, but it has to deal with some short-term problems first. UnitedHealth Group has consistently improved its earnings over the years. In the year 2015, diluted earnings per share was only $6.01. Looking at the trailing twelve months, the number has reached $23.88. Over the past decade, the amount has almost quadrupled. It is even more impressive that the growth has been steady over the years. For many years, UnitedHealth kept increasing its profits, demonstrating the power of its varied businesses and strict management. The only major drop in EPS happened in 2024, with the figure reaching $15.51. Although this was an unusual dip in the company's history, it is on track for a solid recovery in 2025, and first-quarter adjusted EPS was $7.20. Looking into the future, analysts believe the trend will not stop. Even though 2025 is, in some ways, a year of recovery with a projected EPS of $22.59, the company's growth kicks in afterward. By 2026, analysts predict EPS will increase to $26.40, and then keep growing at double-digit rates, aiming for $45.83 by 2030. Source: Author generated based on historical data All in all, despite some occasional setbacks, UnitedHealth's future growth is steady, so patient investors are still in a position to be rewarded. The increase in EPS matches the upward trend in revenue per share. It highlights the company's steady growth and increased success. In the year 2015, the company's revenue per share was $162.47. Now, that figure is $443.16 TTM. That's a 170% jump in ten years, which clearly shows the company is making better use of its growth to help shareholders. What's most promising is that this growth keeps happening consistently. Revenue per share has increased year after year and stayed strong through different economic conditions and impacts on the industry. It is a result of the company attracting more members and expanding its main businesses, UnitedHealthcare and Optum. Once more, this trend keeps happening in the future. Revenue forecasts keep going up from $449.81 billion in 2025 to more than $591 billion by 2030. Minor changes in growth do not stop the company from expanding and creating more value for its shareholders. Source: Author generated based on historical data UnitedHealth Group's free cash flow per share is a reliable sign of how well the company is financially and operationally. The amount of free cash flow per share in 2015 was $8.46. Afterward, the company increased this number, reaching $26.82 for the TTM, which is more than three times higher than its value a decade back. What stands out about this growth is that it follows closely in line with the company's earnings trajectory. Therefore, we see that UnitedHealth's profits are being turned into cash that can be used to strengthen the business, cut debt, or be given back to its shareholders. Being that efficient is not common in an industry that relies heavily on capital like healthcare. UnitedHealth Group gives investors a good dividend since the dividend yield is 2.92% and the payout ratio is only 30%, which suggests that dividends could increase in the future. It's worth noting that over the past 5 years, the company has seen a 14.6% growth in its dividend, which tops inflation and profits long-term investors. Through ten years of constant raises, the yield on cost increases to 15.38%. Although UNH is offering a high yield now, low buybacks mean most capital is shared through dividends. UnitedHealth Group looks deeply undervalued right now. According to GuruFocus, the stock is trading about half its worth, as the fair value is $633.16 but it is currently trading at $303.22. There is a massive disconnect here, and it's very unusual for a company as stable as UNH to deviate so much from its fair value estimate. Valuation multiples are also telling the same story. The forward P/E of this stock is 13.42, which is much lower than the average of 17.66, giving a discount of 23.98%. The company's forward EV/EBITDA of 9.61 is better than the sector's ratio of 11.79. On a price-to-sales ratio, UNH is trading at 0.61 times its projected sales, while the healthcare industry is pricing in at 3.43xa discount of 82%. All in all, UNH gives you both quality and value. Almost all of the valuation measures suggest that the company is undervalued in terms of its earnings, sales, and cash flow. Even though the stock is built on solid foundations and pays out more in dividends each year, it still trades at a lower price than its competitors. As a result, long-term investors can take advantage of acquiring a leader in healthcare at a much lower price than its actual value. When measured against companies like Humana (HUM, Financial) and HealthEquity (HQY, Financial), UnitedHealth Group is still a good buy. Because its forward P/E is lower than HUM's 14.1 times and much lower than HQY's 30 times, it attracts those who want to invest for growth as well as value. Considering price-to-sales, UNH trades at 0.68 times, making it more valuable than HQY's 7.8 while being slightly higher than HUM's very low 0.23. On the EV/EBITDA ratio, UNH stands at 9.6x forward, quite similar to HUM's 9.2x and much less than HQY's 19.2x. All in all, UNH is well-balanced by giving investors scale, profits, dividend growth, and a reasonably attractive price. HUM also does well in various areas, especially when it comes to managing expenses and the way the company works. But in the long run, investors admire UNH for its consistent results and potential to increase. Source: Author generated based on data Going forward, I feel UnitedHealth Group (NYSE:UNH) is well-positioned to achieve a price target of $395$410 in the next year and possibly surpass $525$550 by 2027. Despite the stock's recent volatility, the numbers, the company's health, and the outlook seem to fit together nicely. Let's begin our discussion with the short term. Despite many years of increasing earnings and a high rate of cash conversion, UNH is only valued at 13.4 times its future earnings when the stock is trading at $303. Healthcare companies, on the other hand, have a forward P/E of about 17.6, and UNH has generally had a forward P/E between 18x and 20x during calm times. If UNH is valued at just 17 times the expected FY2025 EPS of $22.59, the price would come to $384. At 18x, If stability comes back and the new leaders reassure everyone, the stock could increase to $406. The story gets even better as you look further into the future. Analysts are predicting that EPS will rise to $45.83 by 2030, meaning it will be about double the current earnings in just five years. Multiply the earnings by 15, and the share price comes out to $687. But, let's narrow our focus to conservatism, and for 2027, the predicted EPS is about $34.50. At this multiple of 15x, the price comes out to $517if the market recovers, shares could climb to $550 or more due to the 16x or 17x rating. If the DOJ investigation ends well and Hemsley's efforts to cut costs are successful, the company should do well over the next few quarters. We are not just discussing theory here. Since 2015, UNH's free cash flow per share has more than tripled, its revenue per share has nearly tripled too, and it still has some of the top dividend growth rates in healthcare. Such consistency, size, and under-valuation are hard to find in one company. Let's look at how Wall Street views this area. Looking at the chart, analysts foresee that the price of Apple shares might rise by 26.2% to $382.80 in the next 12 months. It is estimated that the cost can fall anywhere from $270 to $677. To conclude, although there may be short-term ups and downs, it looks like disciplined, patient investors will find more favorable long-term conditions. When Andrew Witty suddenly left his CEO post in May because of profit problems and dropped 2025 guidance, UNH shares fell over 12% to their lowest point in five years and wiped out more than $250 billion in market value. As a consequence, the board brought back former CEO Stephen Hemsley (who headed the company from 2006 to 2017). Within only a few days, Hemsley made a big step by buying nearly 86,700 shares worth about $25 million for $288.60 per share. Hemsley, together with the CFO and several directors, voted to keep the company's value high, and shares rose by about 8% the following trading day. What does it imply? It is clear that the management views the falling share price of UNH as a good time to purchase. The fact that Hemsley has invested his money shows how much he believes in the company after all it has achieved. Yet, this is not a case of blind faith: the company is dealing with an ongoing investigation, higher medical costs in Medicare Advantage, and a cyberattack it suffered recently. From a strategic point of view, all this buying in UNH suggests that the company's leaders believe the worst has passed and risks for the stock are low. The guru trading chart has an interesting narrative. Although UnitedHealth's stock has gone down recently, gurus have been buying it more frequently. Many green bars are appearing, both early in 2024 and again later in 2025, showing that some informed investors are looking at the dip as an opportunity to buy instead of a warning sign. This trend can be seen in the investor's stock portfolio. Vanguard is still the biggest shareholder, but it slightly reduced its holdings. I'm also paying attention to Ken Fisher (Trades, Portfolio) , who bought much more, a solid 52%, and Jeremy Grantham (Trades, Portfolio) , who increased his holding by over 7%. Though there is selling and shares are reduced as well, institutions tend to be cautiously upbeat. Even though UnitedHealth's future looks bright, investors should still pay attention to the risks in the near term. The DOJ is currently investigating the business for possible Medicare Advantage fraud, such as upcoding and billing errors, which is a very serious matter that could result in being fined or charged in court. At the same moment, Washington is paying more attention to supervision. Should reforms reduce the inflation of risk scores or Medicare allowance for nurse practitioners, it could affect the profitability of Medicare Advantage. Q1 faced some issues because the higher use of medical services caused the medical loss ratio to increase to around 85%, and Optum is still learning to handle CMS's updated risk model. Because of these pressures, there could be more budget reductions for guidance. However, the bad news appears to be mostly factored into share prices. For careful investors who believe the company will survive, this could present an opportunity to buy long-term. The headlines can be very tempting, but stepping back, it appears that UnitedHealth is still a powerhouse lurking in plain sight. It is the same old stuff but with a different sentiment. The long-term story is still in place with the reinstatement of Stephen Hemsley, a recent insider purchase, and a long history of expertise in Medicaid-managed care and the Optum platform in value-based care. Most of that bad news, including the increases in care costs, and regulatory noise, appears to be reflected in price. Sentiment can change at any minute as long as we hear a resolution to the DOJ investigation, a slowdown in the trend of rising Medicare costs, or upbeat guidance in coming quarters. Any of those may be the spark. In the meantime, the stock is currently trading at one of the most attractive valuations it has seen in years, and the set-up is of the sort long-term investors tend to reflect back on with gratitude. If you are waiting to have a clear picture, you may miss the opportunity. However, to the patient and longer-term investors, this may be one of those times when interceding in soreness results in actual payoff. In other words, this just might be a smart time to lean in and buy the stock. This article first appeared on GuruFocus. Sign in to access your portfolio